NeoGenomics logo

NeoGenomicsNASDAQ: NEO

Profile

Sector:

Healthcare

Country:

United States

IPO:

16 March 2004

Next earnings report:

20 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.97 B
-60%vs. 3y high
81%vs. sector
-vs. 3y high
-vs. sector
-49%vs. 3y high
60%vs. sector
-69%vs. 3y high
49%vs. sector

Price

after hours | Wed, 20 Nov 2024 23:12:39 GMT
$15.36+$0.47(+3.16%)

Dividend

No data over the past 3 years
$167.82 M$173.09 M
$167.82 M-$17.70 M

Analysts recommendations

Institutional Ownership

NEO Latest News

NeoGenomics (NEO) Upgraded to Strong Buy: Here's What You Should Know
zacks.com06 November 2024 Sentiment: POSITIVE

NeoGenomics (NEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

NeoGenomics, Inc. (NEO) Q3 2024 Earnings Call Transcript
seekingalpha.com05 November 2024 Sentiment: POSITIVE

NeoGenomics, Inc. (NASDAQ:NEO ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Chris Smith - Chief Executive Officer Jeffrey Sherman - Chief Financial Officer Warren Stone - Chief Commercial Officer Kareem Saad - Head, Strategy and Transformation Andrew Lukowiak - Chief Innovation Officer Nate Montgomery - Vice President, Medical Services Melody Harris - Chief Operations Officer and President, Informatics Conference Call Participants Andrew Brackman - William Blair David Westenberg - Piper Sandler Mike Matson - Needham & Company Matthew Hewitt - Craig-Hallum Capital Group Prashant Kota - Goldman Sachs Mark Massaro - BTIG Mason Carrico - Stephens, Inc. John Kim - Bank of America Andrew Cooper - Raymond James Puneet Souda - SVB Leerink Operator Welcome to the NeoGenomics Third Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.

Wall Street Analysts Believe NeoGenomics (NEO) Could Rally 51.29%: Here's is How to Trade
zacks.com04 November 2024 Sentiment: POSITIVE

The consensus price target hints at a 51.3% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

NEO Battery Materials Announces Closing of Non-Brokered Private Placement
globenewswire.com28 October 2024 Sentiment: POSITIVE

TORONTO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “C o mpan y”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce that it has closed the non-brokered private placement (the “Offering”) of 2,000,000 units (the “Units”) of the Company at the price of $0.40 CAD per Unit (the “Offering Price”) for gross proceeds of $800,000 CAD.

NEO Battery Materials Signs Letter of Intent for Joint Venture with Lotus Energy Recycling
globenewswire.com21 October 2024 Sentiment: POSITIVE

TORONTO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “C o mpan y”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce the signing of a non-binding Letter of Intent (“LOI”) with collaborating partner, Lotus Energy Recycling (“Lotus”) on October 8, 2024. The LOI outlines the intent to form a joint venture (“JV”) focused on recycling end-of-life photovoltaic (PV) cells and solar panels in North America. Recovering valuable silicon materials for the lithium-ion battery supply chain will be a key emphasis of the project. There are no material terms or considerations with respect to the LOI.

NEO Battery Materials Signs Joint Development Agreement with Fortune Global 500 Chemical Materials Company
globenewswire.com07 October 2024 Sentiment: POSITIVE

TORONTO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “C o mpan y”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce the Joint Development Agreement (“Agreement” or the “JDA”) with a Fortune Global 500, multinational chemical materials company (the “JDA Partner”). The JDA Partner will remain confidential due to competitive strategy and protection of proprietary technologies.

AerCap Signs Lease Agreements with New Customer Azerbaijan Airlines for Six New Airbus A320NEO Family Aircraft
prnewswire.com02 October 2024 Sentiment: POSITIVE

DUBLIN , Oct. 2, 2024 /PRNewswire/ -- AerCap Holdings N.V. ("AerCap" or the "Company") (NYSE: AER) today announced that it has signed lease agreements with Azerbaijan Airlines ("AZAL") for six new Airbus CFM LEAP powered aircraft, including three A320neos and three A321neos which are scheduled to deliver in 2026.

NeoGenomics Inc (NEO) Shares Up 3.95% on Oct 2
gurufocus.com02 October 2024 Sentiment: POSITIVE

Shares of NeoGenomics Inc (NEO, Financial) surged 3.95% in mid-day trading on Oct 2. The stock reached an intraday high of $14.36, before settling at $14.36, up from its previous close of $13.81.

NEO Battery Materials Announces Closing of NBM Korea Co. Share Purchase Agreement
globenewswire.com06 September 2024 Sentiment: POSITIVE

TORONTO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, has closed the Share Purchase Agreement (the “Transaction”) of NBM Korea Co., Ltd., (“NBM Korea”) with Automobile & PCB Inc. (“A&P”) pursuant to TSX Venture Exchange (the “Exchange”) Policy 5.3 – Acquisitions and Dispositions of Non-Cash Assets (“Policy 5.3”) but is contingent on fulfilling certain conditions required by the Exchange for final acceptance.

NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
businesswire.com29 August 2024 Sentiment: POSITIVE

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, Sept. 6, 2024 at 10:45 a.m. ET in New York City.

  • 1(current)
  • 2
  • 3

What type of business is NeoGenomics?

NeoGenomics, Inc. is one of the leading companies in cancer diagnostics and pharmaceutical services, serving oncologists, pathologists, pharmaceutical companies, academic centers, and other specialists with innovative diagnostic and prognostic tests. The company was founded in 2002, with headquarters located in Fort Myers, Florida, USA. The clinical services segment provides cancer testing services for pathologists, oncologists, dermatologists, and other clinicians representing various communities, hospitals, and centers. The company is a leading provider of molecular sequencing and next-generation testing. The pharmaceutical services segment offers comprehensive testing services to support pharmaceutical clients' oncology programs from discovery to commercialization.

What sector is NeoGenomics in?

NeoGenomics is in the Healthcare sector

What industry is NeoGenomics in?

NeoGenomics is in the Diagnostics & Research industry

What country is NeoGenomics from?

NeoGenomics is headquartered in United States

When did NeoGenomics go public?

NeoGenomics initial public offering (IPO) was on 16 March 2004

What is NeoGenomics website?

https://www.neogenomics.com

Is NeoGenomics in the S&P 500?

No, NeoGenomics is not included in the S&P 500 index

Is NeoGenomics in the NASDAQ 100?

No, NeoGenomics is not included in the NASDAQ 100 index

Is NeoGenomics in the Dow Jones?

No, NeoGenomics is not included in the Dow Jones index

When was NeoGenomics the previous earnings report?

No data

When does NeoGenomics earnings report?

The next expected earnings date for NeoGenomics is 20 February 2025